A detailed history of Price T Rowe Associates Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,322,196 shares of NVCR stock, worth $74.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,322,196
Previous 2,156,021 7.71%
Holding current value
$74.5 Million
Previous $36.9 Million 1.72%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.61 - $23.34 $2.59 Million - $3.88 Million
166,175 Added 7.71%
2,322,196 $36.3 Million
Q2 2024

Aug 14, 2024

SELL
$11.83 - $24.05 $2.64 Million - $5.36 Million
-222,919 Reduced 9.37%
2,156,021 $36.9 Million
Q1 2024

May 15, 2024

BUY
$12.42 - $17.29 $1.56 Million - $2.17 Million
125,715 Added 5.58%
2,378,940 $37.2 Million
Q4 2023

Feb 14, 2024

SELL
$11.13 - $15.78 $1.24 Million - $1.76 Million
-111,234 Reduced 4.7%
2,253,225 $33.6 Million
Q3 2023

Nov 14, 2023

SELL
$16.15 - $42.35 $2.92 Million - $7.67 Million
-181,006 Reduced 7.11%
2,364,459 $38.2 Million
Q2 2023

Aug 14, 2023

SELL
$40.29 - $82.51 $4.44 Million - $9.09 Million
-110,221 Reduced 4.15%
2,545,465 $106 Million
Q1 2023

May 15, 2023

BUY
$56.44 - $118.81 $27.5 Million - $57.9 Million
487,255 Added 22.47%
2,655,686 $160 Million
Q4 2022

Feb 14, 2023

SELL
$63.98 - $85.37 $13 Million - $17.4 Million
-203,555 Reduced 8.58%
2,168,431 $159 Million
Q3 2022

Nov 14, 2022

BUY
$67.99 - $89.57 $2.76 Million - $3.64 Million
40,619 Added 1.74%
2,371,986 $180 Million
Q2 2022

Aug 15, 2022

BUY
$56.6 - $89.9 $12.4 Million - $19.6 Million
218,216 Added 10.33%
2,331,367 $162 Million
Q1 2022

May 16, 2022

BUY
$60.15 - $84.52 $37.7 Million - $53 Million
626,983 Added 42.19%
2,113,151 $175 Million
Q4 2021

Feb 14, 2022

BUY
$75.08 - $121.99 $4.03 Million - $6.55 Million
53,701 Added 3.75%
1,486,168 $112 Million
Q3 2021

Nov 15, 2021

SELL
$116.17 - $194.55 $15.9 Million - $26.7 Million
-137,018 Reduced 8.73%
1,432,467 $166 Million
Q2 2021

Aug 16, 2021

BUY
$130.4 - $225.58 $44.6 Million - $77.1 Million
341,783 Added 27.84%
1,569,485 $348 Million
Q1 2021

May 17, 2021

SELL
$124.11 - $190.17 $1.3 Million - $2 Million
-10,502 Reduced 0.85%
1,227,702 $162 Million
Q4 2020

Feb 16, 2021

BUY
$112.16 - $174.14 $139 Million - $216 Million
1,238,204 New
1,238,204 $214 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.37B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.